The Trump Administration: Seven More Things To Watch Out For
Executive Summary
Beyond pricing, industry experts weigh in on how the next administration has shifted expectations across a range of areas – including tax reform, FDA standards and the Cancer Moonshot Initiative.
You may also be interested in...
Flu Hunters: House Committee Searches For Pandemic Plan
Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.
On The Sunny Side Of Trump Street: Biopharma Ready For Tax Reform
Industry experts expressed optimism for tax reform at the Biotech Showcase and J.P. Morgan Healthcare Conference, though there is concern about the future of the federal Small Business Innovation Research program.
Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?
President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.